エピソード

  • Update on Reproxalap PDUFA Timing

    Update on Reproxalap PDUFA Timing
    2025/12/17
    Aldeyra provides an update on the timing of its dry eye disease treatment candidate reproxalap; Ocular Therapeutix pursues an accelerated NDA pathway for wet AMD therapy Axpaxli; and companies with late-stage drug candidates announce FDA submission plans. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    9 分
  • New Glaucoma Technologies Advance in Clinical Development

    New Glaucoma Technologies Advance in Clinical Development
    2025/12/10
    Companies with plans to commercialize glaucoma technologies in the US reach clinical milestones; Haag-Streit announces the global launch of a new Indirect ROP Laser Module; and EyeYon Medical gets approval to initiate a US clinical study of its EndoArt corneal implant. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    5 分
  • Eylea HD Approved for RVO and Extended Dosing

    Eylea HD Approved for RVO and Extended Dosing
    2025/12/03
    Eylea HD gains FDA approval for a new indication and dosing schedule; Lucentis biosimilar Byooviz receives a key approval in Europe; and Belite Bio announces topline results from its global phase 3 trial evaluating its drug candidate for Stargardt disease. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    5 分
  • Leaders Discuss Emerging Technologies in Glaucoma

    Leaders Discuss Emerging Technologies in Glaucoma
    2025/11/26
    Several new technologies are emerging that aim to transform the way glaucoma is treated and managed. Many of these technologies are now available to patients outside of the United States, with the goal of expanding availability to the US and beyond. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    13 分
  • Live Coverage of B+L Investor Day

    Live Coverage of B+L Investor Day
    2025/11/18
    Bausch + Lomb outlines a strategic path to innovation and growth at its Investor Day; Apellis reports new 5-year data examining Syfovre and GA progression; and two global organizations for restoring sight merge. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    7 分
  • Ryjunea Approved in the UK for Myopia

    Ryjunea Approved in the UK for Myopia
    2025/11/12
    Sydnexis receives another regulatory approval for its childhood myopia eye drop; Eli Lilly makes two major investments in ophthalmology; and Nanoscope reports new long-term data for its intravitreal optogenetic therapy for RP. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    5 分
  • Ophthalmic Executives Provide Company Updates (Part 2 of 2)

    Ophthalmic Executives Provide Company Updates (Part 2 of 2)
    2025/11/05
    Leaders of several ophthalmic companies provide updates on their pipeline and new products in this special edition of Eyewire News the Podcast. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    15 分
  • Ophthalmic Executives Provide Company Updates (Part 1 of 2)

    Ophthalmic Executives Provide Company Updates (Part 1 of 2)
    2025/10/29
    Leaders of several ophthalmic companies provide updates on their pipeline and new products in this special edition of Eyewire News the Podcast. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    17 分